Reach Us +1-218-451-2974


Richard Mohs | OMICS International
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Richard Mohs

Lilly Research Laboratories.


 Richard is an eminent clinical researcher with a long and distinguished track record of expertise in Alzheimer’s drug development and clinical trial design,” said Jerry McLaughlin, President and CEO of AgeneBio. “His addition to our outstanding research and development team well positions AgeneBio as we rapidly advance AGB101 to our HOPE4MCI Phase 3 clinical trial.” “AGB101 is a promising drug candidate for addressing aMCI due to Alzheimer’s disease – or prodromal Alzheimer’s – with the potential to be the first and only therapy to address brain network imbalance that leads to memory loss and brain atrophy,” said Dr. Mohs. “With multiple preclinical models demonstrating efficacy and positive Phase 2 results in hand, I look forward to working with the AgeneBio team to initiate the HOPE4MCI Phase 3 trial next year.”


Research Interest

 Alzheimer’s disease, Psychiatry